1. Home
  2. TROX vs DMRA Comparison

TROX vs DMRA Comparison

Compare TROX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tronox Holdings plc (UK)

TROX

Tronox Holdings plc (UK)

HOLD

Current Price

$8.00

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$24.60

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TROX
DMRA
Founded
2018
2011
Country
United States
United States
Employees
N/A
7
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
TROX
DMRA
Price
$8.00
$24.60
Analyst Decision
Hold
Buy
Analyst Count
8
2
Target Price
$6.36
$43.00
AVG Volume (30 Days)
2.9M
279.5K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
2.07%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,898,000,000.00
N/A
Revenue This Year
$6.94
N/A
Revenue Next Year
$5.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.86
$16.50
52 Week High
$10.59
$28.76

Technical Indicators

Market Signals
Indicator
TROX
DMRA
Relative Strength Index (RSI) 38.83 48.32
Support Level $3.29 $22.71
Resistance Level $10.36 $28.00
Average True Range (ATR) 0.59 1.84
MACD -0.25 -0.13
Stochastic Oscillator 0.59 52.01

Price Performance

Historical Comparison
TROX
DMRA

About TROX Tronox Holdings plc (UK)

Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: